Search clinical trials for: Kit mutation

Total 11338 results

Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, Korea, Republic of, Belgium, China, Japan, Taiwan, Denmark, Germany, Israel, Italy, United Kingdom, Bulgaria, Portugal, Switzerland, Greece, Turkey, Sweden, France, Singapore, Mexico, Spain, Netherlands, Poland, Brazil, A... and more
Children's Hospital of Soochow University

Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

AML, Childhood | C-KIT Mutation | Refractory AML | Relapse/Recurrence | Core Binding Factor Acute Myeloid Leukemia

China
Sarcoma Alliance for Research through Collaboration
Dana-Farber Cancer Institute; Cogent Biosciences, Inc.; The Life Raft Group

Not yet recruiting

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Gastrointestinal Stromal Tumors | GIST

United States
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

C-KIT Mutation
M.D. Anderson Cancer Center
Bayer

Not yet recruiting

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Gastrointestinal Stromal Tumors

United States
Columbia University
National Institute on Aging (NIA)

Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Lumbar Spinal Stenosis | Cardiomyopathy, Hypertrophic | Cardiac Amyloidosis | ATTR Amyloidosis Wild Type | ATTR Gene Mutation | ATTRV122I Amyloidosis

United States
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
Xijing Hospital

Recruiting

Exploring the Molecular Mechanism Based on KIT Mutation (EMMBKM)

GIST

China
The First Affiliated Hospital of Soochow University

Recruiting

Avapritinib in CBF-AML With KIT Mutations

Core Binding Factor Acute Myeloid Leukemia | KIT Mutation-Related Tumors

China
Deciphera Pharmaceuticals LLC

Recruiting

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)

GIST

United States, Korea, Republic of, Spain, France, Taiwan, Italy, Australia, Canada, Germany, United Kingdom, Netherlands, Brazil, Chile, Poland
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Recruiting

Genetic Characterization of Cardiomyopathies (POLICARDIOMIO2021)

Cardiomyopathies

Italy
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer

China
Cristina Avendaño Solá

Recruiting

Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial) (EARLY-GENE)

Cardiomyopathy, Dilated

Spain
Eisai Co., Ltd.

Recruiting

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Lymphoma, Follicular

Japan
Tenaya Therapeutics

Recruiting

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy (MyCLIMB)

Cardiomyopathy

United States, Canada, United Kingdom, Spain
Centre Leon Berard

Recruiting

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

C-KIT Mutation | Metastatic Gastrointestinal Stromal Tumor (GIST) | Advanced Gastrointestinal Stromal Tumor (GIST)

France
Lady Davis Institute

Recruiting

Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Acneiform Eruptions | Cancer, Treatment-Related

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Prognostic Stage IIIC Breast Cancer AJCC v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Locally... and other conditions

United States
RasCal Therapeutics, Inc.

Recruiting

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Glioblastoma | Pancreatic Cancer | Lung Cancer | Colon Cancer | Advanced Malignant Solid Neoplasm | RAS Mutation

United States
Weill Medical College of Cornell University
Basser Research Center for BRCA

Recruiting

FaCT Trial (Facilitated Cascade Testing Trial)

BRCA1 Mutation | BRCA2 Mutation

United States
National Cancer Institute (NCI)

Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Gastric Cancer | Gastric Neoplasm | Gastrointestinal Stromal Tumor (GIST) | Gastrointestinal Stromal Sarcoma | Gastrointestinal Stromal Neoplasm

United States
University of Pennsylvania

Recruiting

Evaluating Cascade Communication Methods (ECHO)

BRCA1 Mutation | BRCA2 Mutation

United States
Mark Vincent
AstraZeneca

Recruiting

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)

Non-Small Cell Lung Cancer

Canada
AB Science

Recruiting

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Indolent Systemic Mastocytosis

France, Netherlands, Germany, United Kingdom, Russian Federation, Poland, Romania, Ukraine
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
University College, London
NIHR Rare Diseases Translational Research Collaboration; Barts Cardiovascular...

Recruiting

The Deep Phenotype of Lamin A/C Cardiomyopathy

Lamin A/C Gene Mutation | Dilated Cardiomyopathy, Familial

United Kingdom
The First Hospital of Jilin University

Recruiting

Effects of Different Genetic Mutations on Prognosis in sMPLC Adenocarcinoma Patients

Gene Mutation

China
Yonsei University

Recruiting

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Melanoma

Korea, Republic of
Indiana University
American Heart Association

Recruiting

Pediatric Cardiomyopathy Mutation Analysis

Cardiomyopathies | Dilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Restrictive Cardiomyopathy | Left Ventricular Non-compaction Cardiomyopathy

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
Institut Curie

Recruiting

COsegregation of VARiants in Panel of Genes (COVAR)

Genetic Predisposition | Gene Mutation-Related Cancer

France, Guadeloupe, Martinique, Réunion
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Surveillance of Tabrecta Tablets

Non-small Cell Lung Cancer

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Germany, Japan, China, Israel, Belgium, Italy, France, Taiwan, Thailand, Korea, Republic of, Malaysia, Spain, Hungary, Turkey, Portugal, India, Brazil, Poland, Australia, Russian Federation, Mexico, Puerto Rico, U... and more
23andMe, Inc.

Active, not recruiting

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Clear Cell Renal Cell Carcinoma | Fallopian Tube Cancer | Solid Tumor | Neuroendocrine Tumors | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma | Extensive-stage Small-cell Lung Cancer | MSI-H Cancer | Cancer With A High Tumor Mutational Burden

United States, Canada
Amgen

Active, not recruiting

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak300)

Colorectal Cancer (CRC)

France, Spain, Korea, Republic of, United States, United Kingdom, Taiwan, Italy, Greece, Australia, Japan, Germany, Mexico
Nanjing First Hospital, Nanjing Medical University

Completed

Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)

Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility to

China
Pfizer

Terminated

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Dilated Cardiomyopathy | Lamin A/C Gene Mutation

United States, Spain, Canada, Belgium, Italy, Argentina, Mexico, Netherlands, Norway, United Kingdom
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
AstraZeneca

Completed

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (AURA2)

Non Small Cell Lung Cancer

Italy, United States, Canada, Korea, Republic of, Japan, Taiwan, Hong Kong, Spain
Takeda

Completed

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (PARADIGM)

Colorectal Cancer

Japan
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722)

Non-Small-Cell Lung Carcinoma

United States, China, Taiwan, Spain, Korea, Republic of, France, Canada, Hong Kong, Japan, Singapore
Sameek Roychowdhury

Active, not recruiting

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Malignant Neoplasm

United States
AstraZeneca

Active, not recruiting

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3)

Anticancer Treatment

United States, France, Germany, Spain, Sweden, United Kingdom, Canada, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, China, Taiwan, Hong Kong, Netherlands, Australia, Mexico
Blueprint Medicines Corporation

Active, not recruiting

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States, Canada, United Kingdom, France, Netherlands, Italy, Spain, Austria, Denmark, Germany, Norway, Poland
Centre Oscar Lambret
CTD-CNO; Laboratoire PRISM

Active, not recruiting

Radical Fimbriectomy for Young BRCA Mutation Carriers (Fimbriectomy)

BRCA1 Mutation | BRCA2 Mutation | Hereditary Breast and Ovarian Cancer

France

Search clinical trials for: Kit mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations